Evidence map›Paper›PMID 37498938›Full record

ArticlePLoS neglected tropical diseases2023

Health economic evaluation of strategies to eliminate gambiense human African trypanosomiasis in the Mandoul disease focus of Chad.

Marina Antillon, Ching-I Huang, Samuel A Sutherland, Ronald E Crump, Paul R Bessell, Alexandra P M Shaw, Iñaki Tirados, Albert Picado, Sylvain Biéler, Paul E Brown and 8 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Accelerating Progress Towards the 2030 Neglected Tropical Diseases Targets: How Can Quantitative Modeling Support Programmatic Decisions?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 3 countries.

Marina AntillonSwiss Tropical and Public Health Institute, Basel, Switzerland.ORCID 0000-0002-0235-6030
Ching-I HuangZeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, United Kingdom.ORCID 0000-0002-8329-8310
Samuel A SutherlandZeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, United Kingdom.ORCID 0000-0003-1794-9813
Ronald E CrumpZeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, United Kingdom.ORCID 0000-0002-1497-2586
Paul R BessellIndependent Consultant, Edinburgh, United Kingdom.ORCID 0000-0002-7901-969X
Alexandra P M ShawInfection Medicine, Deanery of Biomedical Sciences, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0003-2919-5043
Iñaki TiradosDepartment of Vector Biology, Liverpool School of Tropical Medicine, United Kingdom.ORCID 0000-0002-9771-4880
Albert PicadoFoundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.ORCID 0000-0001-7344-628X
Sylvain BiélerFoundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.ORCID 0000-0001-6994-9853
Paul E BrownZeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, United Kingdom.ORCID 0000-0002-8764-4583
Philippe SolanoInstitut de Recherche pour le Développement, UMR INTERTRYP IRD-CIRAD, Université de Montpellier, Montpellier, France.ORCID 0000-0002-4351-3506
Severin MbaindaProgramme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Moundou, Chad.
Justin DarnasProgramme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Moundou, Chad.
Xia Wang-SteverdingZeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, United Kingdom.ORCID 0000-0001-6915-2588
Emily H CrowleyZeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, United Kingdom.ORCID 0000-0002-5121-4979
Mallaye PekaProgramme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Moundou, Chad.
Fabrizio TediosiSwiss Tropical and Public Health Institute, Basel, Switzerland.ORCID 0000-0001-8671-9400
Kat S RockZeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, United Kingdom.ORCID 0000-0001-8414-7648
University of Warwick · GBFIND · CHSwiss Tropical and Public Health Institute · CHCentre de Coopération Internationale en Recherche Agronomique pour le Développement · FRLiverpool School of Tropical Medicine · GBUniversity of Edinburgh · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human African trypanosomiasis, caused by the gambiense subspecies of Trypanosoma brucei (gHAT), is a deadly parasitic disease transmitted by tsetse. Partners worldwide have stepped up efforts to eliminate the disease, and the Chadian government has focused on the previously high-prevalence setting of Mandoul. In this study, we evaluate the economic efficiency of the intensified strategy that was put in place in 2014 aimed at interrupting the transmission of gHAT, and we make recommendations on the best way forward based on both epidemiological projections and cost-effectiveness. In our analysis, we use a dynamic transmission model fit to epidemiological data from Mandoul to evaluate the cost-effectiveness of combinations of active screening, improved passive screening (defined as an expansion of the number of health posts capable of screening for gHAT), and vector control activities (the deployment of Tiny Targets to control the tsetse vector). For cost-effectiveness analyses, our primary outcome is disease burden, denominated in disability-adjusted life-years (DALYs), and costs, denominated in 2020 US$. Although active and passive screening have enabled more rapid diagnosis and accessible treatment in Mandoul, the addition of vector control provided good value-for-money (at less than $750/DALY averted) which substantially increased the probability of reaching the 2030 elimination target for gHAT as set by the World Health Organization. Our transmission modelling and economic evaluation suggest that the gains that have been made could be maintained by passive screening. Our analysis speaks to comparative efficiency, and it does not take into account all possible considerations; for instance, any cessation of ongoing active screening should first consider that substantial surveillance activities will be critical to verify the elimination of transmission and to protect against the possible importation of infection from neighbouring endemic foci.

Indexed as

Trypanosoma brucei bruceiTrypanosomiasis, AfricanAnimalsChadCost-Benefit AnalysisHumansTrypanosoma brucei gambiense

Identifiers

PMID37498938
PMCPMC10409297
OpenAlexW4385324170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.